BIOLASE, Inc. reiterated earnings guidance for the Full-Year of 2024. For the year, the company expects net revenue to increase between 6% and 8% year over year to between $52 million and $53 million. This reflects the continued adoption of lasers and consumables by the dental community, including general dentists, dental specialists, dental hygienists, and group practice entities (DSOs), offset by the challenging business environment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1736 USD | +1.64% | +4.83% | -84.53% |
14/05 | Wall Street Set to Open Flat Tuesday as Key Inflation Gauge Rises More Than Expected | MT |
14/05 | Top Premarket Decliners | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-84.53% | 5.7M | |
+7.31% | 217B | |
+12.99% | 190B | |
+19.71% | 143B | |
+30.60% | 111B | |
+0.65% | 64.59B | |
+15.23% | 52.36B | |
+2.06% | 48.45B | |
-5.49% | 38.03B | |
-0.22% | 35.6B |
- Stock Market
- Equities
- BIOL Stock
- News BIOLASE, Inc.
- BIOLASE, Inc. Reiterates Earnings Guidance for the Full-Year of 2024